Earnings Ahead

SRNE - Sorrento Therapeutics, Inc.

0.2953 -0.012 -3.91

  1. Home
  2. Healthcare
  3. SRNE
Sorrento Therapeutics, Inc.

Sorrento Therapeutics, Inc.

About

Profile

Headquarters

California, United States

Intraday

High
-
Low
-

52-week

High
-
Low
-

SRNE



 
...

Available for logged in users only.



The multiple price alert feature will smartly add or remove $1 if your alert was hit.
It's only available if you are logged in, a V.I.P. member or if you are using the AI chrome extension.

Contact us via Twitter if you are interested in trying it out.
  • Sorrento rises as FDA clears Phase 1 trial for COVID-19 therapeutic
  • Sorrento Therapeutics subsidiary Scilex to acquire Ancora Medical
  • MFGP, SRNE and OPEN among pre market losers
  • Sorrento unit Scilex gets license to commercialize Romeg's gout treatment Gloperba
  • Inovio Pharma, Bionano Genomics among health care stocks to join Russell Microcap Index; Tonix Pharma, iBio to leave
  • Sorrento's Scilex repurchases $41.4M notes ahead of going public with SPAC Vickers Vantage
  • Sorrento' unit Scilex begins dosing in mid-stage study of SP-103 for lower back pain
  • Sorrento stock rises after FDA gives nod to begin phase 2 study of abivertinib to treat prostate cancer
  • Scilex, part of Sorrento Therapeutics names new CFO
  • Sorrento subsidiary Scilex expands distribution network to national, regional wholesalers
  • Sorrento gets FDA nod to start early-stage trial for intravenous COVID-19 therapy
  • Sorrento granted FDA clearance to start late-stage trial for COVID-19 therapy
  • Morgan Stanley projects about a third of biotechs will need financing in 2022
  • Sorrento subsidiary Scilex to enter deal for $5 billion equity financing
  • Sorrento subsidiary Scilex to go public in SPAC merger with Vickers Vantage
  • Sorrento Therapeutics sciatica pain treatment meets primary endpoint in phase 3 trial
  • Sorrento granted FDA nod to start clinical trial for intranasal COVID-19 therapy
  • Sorrento' COVISHIELD shows neutralizing activity vs Omicron subvariants
  • Sorrento acquires a majority stake in FortuneBio to meet demand for rapid COVID-19 test
  • Sorrento rises 7% as STI-1558 neutralizes omicron in cell-based tests
PEERS
/EXEL

EXEL

/KPTI

KPTI

/XLV

XLV

Earnings History

Date EPS / Forecast Revenue / Forecast
November 11, 2021 -0.4 / -0.285 12.06M / 7.79M Beat!
August 11, 2021 -0.365 / -0.365 8.37M / 8.37M Beat!
May 11, 2021 -0.07 / 0.42 8.68M / 18.23M
March 12, 2021 -0.27 / 2.76 9.61M / 10.7M Beat!
November 6, 2020 -0.33 / -0.205 11.75M / 8.69M Beat!
May 12, 2020 -0.36 / -0.36 6.48M / 6.48M
February 26, 2020 -0.42 / -0.4 13.03M / 6.6M Beat!
November 6, 2019 -0.37 / -0.43 5.8M / 6.71M
Date Price Open High Low Vol Change ER
Aug 17 2.115 2.500
2.510
2.060
17.63M -16.07%
Aug 16 2.520 2.670
2.720
2.470
10.10M -8.36%
Aug 15 2.750 2.600
2.750
2.570
6.01M 4.56%
Aug 12 2.630 2.550
2.650
2.490
8.18M 6.05%
Aug 11 2.480 2.690
2.730
2.470
8.68M -7.12%
 
Aug 10 2.670 2.700
2.720
2.620
7.23M 3.09%
Aug 9 2.590 2.700
2.750
2.540
9.63M -6.5%
Aug 8 2.770 2.830
2.945
2.700
8.62M 0.36%
Aug 5 2.760 2.680
2.800
2.640
9.95M 2.22%
Aug 4 2.700 2.660
2.780
2.640
8.48M 1.12%
Aug 3 2.670 2.610
2.827
2.610
10.05M 3.09%
Aug 2 2.590 2.440
2.650
2.340
8.16M 4.86%
Aug 1 2.470 2.570
2.670
2.470
7.22M -5%
Jul 29 2.600 2.580
2.635
2.560
5.57M -0.76%
Jul 28 2.620 2.610
2.720
2.531
6.27M -0.76%
Jul 27 2.640 2.590
2.670
2.522
8.97M 3.94%
Jul 26 2.540 2.580
2.640
2.480
7.24M -1.17%
Jul 25 2.570 2.640
2.720
2.515
6.69M -1.15%
Jul 22 2.600 2.770
2.900
2.600
9.43M -6.14%
Jul 21 2.770 2.920
3.000
2.740
9.05M -3.82%
Jul 20 2.880 2.710
3.090
2.710
15.67M 5.88%
Jul 19 2.720 2.530
2.720
2.460
12.61M 10.12%
Jul 18 2.470 2.600
2.790
2.470
10.71M -5%